Plasticity windows and psychedelic research: where the proposal stands

The report’s plasticity proposal asks whether a period of increased capacity for learning could be paired with different movement, sensory or emotional experiences. Psychedelic research is one reason this possibility appears in the report. The interesting question is the proposed timing of learning—not simply whether a substance produces a noticeable experience.

Direct fibromyalgia evidence is still early

A pilot involving Kevin Boehnke, Jacob Aday and colleagues studied psilocybin-assisted therapy in five adults with fibromyalgia. It combined supervised sessions with psychotherapeutic support and reported preliminary improvements. Without a control group, it cannot separate drug effects from the accompanying therapy, expectations or other influences. 1

This is a feasibility-stage signal. It does not establish effectiveness across the broader fibromyalgia population, and it is not evidence for unsupervised use or for taking small repeated doses outside the studied setting.

The critical-period finding has a replication problem

A 2023 mouse study reported reopening of a social-reward learning critical period after psychedelic exposure. Its discussion of extracellular-matrix-related biology attracted attention as a possible bridge between plasticity and the report’s connective-tissue interests. 2

A later multi-institutional investigation did not reproduce the critical-period reopening result under its experimental conditions. 3 The disagreement is consequential: the original result should not be treated as a settled timetable for learning after a psychedelic.

There is another boundary even if the effect proves reproducible. Extracellular-matrix biology in a mouse brain experiment is not evidence of fascial repair in a human with fibromyalgia. The shared term “matrix” cannot do the work of that missing experiment.

Microdosing and the Stamets-associated combination

Paul Stamets appears in the report because of his association with a proposed combination of psilocybin mushrooms, lion’s mane and niacin. A relevant observational cohort examined microdosing and exploratory combination outcomes. Participants selected their own practices; the design cannot establish that the combinations caused improvement. 4

The cohort, the supervised fibromyalgia pilot and the mouse experiments are three different bodies of evidence. Combining their most promising features into one confident treatment claim would create an intervention that none of them tested.

What the report adds as a hypothesis

The proposed next step is a sequencing question: could an appropriately studied intervention be followed by a carefully chosen learning experience, with outcomes that persist beyond the immediate state? To test it, researchers would need a comparison that isolates the contribution of the sequence, not merely improvement after an intensive treatment package.

Meaningful outcomes would include function and durability, alongside adverse effects and the experience of participants who do not benefit. An account that explains success but has no place for deterioration is incomplete.

How to explore this branch responsibly

This article is a research introduction, not a dosing or combination protocol. The pilot’s screening, supervision and support are part of what was studied, including attention to medical and psychiatric suitability and medications. Those elements cannot be assumed to transfer to an informal setting.

For the systems hypothesis, this remains an open research branch. The useful response to its uncertainty is a more precise experiment—not treating enthusiasm, a dramatic experience or a proposed mechanism as a substitute for that experiment.

Educational publication, not individualized medical advice. Functional Fascia also sells supplements; the studies here did not test our products. Editorial and commercial context · Suggest a correction